Breast cancer is the most common cancer in women worldwide. The standard for detecting it includes clinical exam, mammography and fine-needle aspiration cytology. Our aim was to establish the role of the tru-cut biopsy in the diagnosis of malignant breast lesions. We provide a two-year retrospective clinical study defining 98.67% sensitivity, 100% specificity, 100% positive predictive value, 80% negative predictive value and an overall diagnostic accuracy of 98.73%. In 89.1% of the malignant lesions, the sample was adequate to define the receptor status. Therefore, tru-cut biopsy is an easy, cheap, safe and accurate alternative to fine-needle aspiration cytology in the diagnosis of breast lesions.
Introduction
According to the Bulgarian national cancer register breast cancer is the most common malignancy in women (incidence 26.5%) and the most common reason for cancer death as well. The crude incidence rate in 2013 was 107.2 per 100 000 women [1] .The standard for breast cancer diagnosis includes clinical exam, mammography and fine-needle aspiration cytology (FNAC) . Some recent studies have suggested that tru-cut biopsy (TCB) or core-needle biopsy is in some areas superior to FNAC [2] [3] [4] . FNAC has not achieved any improvement in the preoperative decision-making by surgeons and oncologists. On the other hand, TCB is a new, developing, modern method based on a histopathological study of tissue specimen and it can provide all the clinical information needed. Our aim was to establish the role of tru-cut (core) needle biopsy in the pre-operative diagnosis of breast lesions.
Materials and Methods
A retrospective clinical study was undertaken of all patients who had undergone TCB of breast mass followed by operative treatment between January 2014 and December 2015 at the Department of Surgical Oncology in the University Hospital in 126 DOI: 10.1515/jbcr-2016-0018 Dimitrov D, et al . Diagnostic value of tru-cut biopsy in diagnosing breast lesions Pleven. A total of 79 tru-cut biopsies followed by surgical treatment were performed on patients with palpable lesions during the study period. All lesions were palpable and suspected for malignancy. TCB was performed using a Tru-Cut Each TCB diagnosis was matched with the post-surgical histopathology result and was labeled as follows: true positive (TP) when positive TCB result for malignancy was obtained and carcinoma in histological study of the postsurgical specimen was found; false positive (FP) when positive TCB result for malignancy obtained and no carcinoma in the histological study of the post-surgical specimen was found; false negative (FN) when negative TCB result for malignancy was not verified in the post-surgical histological study and true negative (TN) when negative TCB result for malignancy was verified in the post-surgical histological study.
The formula used for sensitivity (SN) was SN=TP/(TP+FN). Sensitivity was measured as the proportion of malignancies that were correctly identified as such. The formula used for specificity (SP) was SP=TN/(TN+FP). Specificity was measured as the proportion of benign diseases that were correctly identified as such. The formula used for positive predictive value (PPV) was PPV=TP/(TP+FP). PPV was measured as the proportion of positive tests for malignancy that were true positive. The formula used for negative predictive value (NPV) was NPV=TN/(TN+FN). NPV was measured as the proportion of negative malignancy tests that were true negative. The formula used for overall d i a g n o s t i c a c c u r a c y ( O D A ) w a s ODA=(TP+TN)/(FP+FN+TP+TN). ODA was measured as the proportion of all results that were true defined.
Results
The median age of the group was 64 years old (range: 37 to 91). All of the patients were women. All TCB included in this study was in different time window followed by surgical treatment including different types of mastectomy and excision biopsy.
Histopathology after tru-cut biopsies showed 74 (93.7%) malignant lesions and 5 benign lesions (6.3%). Histopathology of the postsurgical specimen showed 75 (94.9%) malignant lesions and 4 benign lesions (5.1%). Comparison of TCB to postsurgical histopathology revealed the following results: 74 true positive cases ( ) zero false positive cases (0%), one false 93.7% , negative case (1.3%) and 4 true negative cases (5.1%), as shown in Table 1 . Therefore, TCB showed sensitivity of 98.67%, 100% specificity, 100% positive predictive value and 80% negative predictive value. The overall diagnostic accuracy We measured a sensitivity of 98.67%, 100% specificity, 100% positive predictive value and 80% negative predictive value. The overall diagnostic accuracy found was 98.73%. There were no false-positive results. There was just one false negative result. One reasons for this could be a sampling error or incorrect size of needles used. Our findings were comparable to those reported in the literature [2] [3] [4] [12] [13] [14] [15] (Table 2) . Most authors have reported results for sensitivity, specificity and PPV that are very close to ours. We believe that the low NPV result that we got was due to the small number of patients with benign disease included in the study. Recent meta-analysis of the diagnostic accuracy of tru-cut biopsy showed the risk of breast cancer despite benign TCB result is less than 1% in US and 4-6% in Europe [16] . Tru-cut biopsy results yield information about receptor status, expression of oncogenes and antioncogenes, thus allowing the administration of exact, modern preoperative chemotherapy. In 128 this way, it benefits the multidisciplinary planning and could also help to change the surgical strategy that is safer for the patient.
Conclusions
Tru cut biopsy is an -easy, cost-effective, safe and accurate alternative to fine needle aspiration -cytology in breast lesions with a diagnosing n accuracy as as 73 Tru-cut biopsy high of 98. %. seems superior to fine needle aspiration cytology in detecting suspicious malignant breast lumps because of the possibility to define the lesion's receptor status. It is also superior to open biopsy in terms of safety, hospital stay, costs, postoperative pain and complications.
